Biosimilars—a fast-growing class of therapeutic products that are highly similar to and have no clinically meaningful differences from existing FDA-approved branded biologics—are poised to significantly change the face of medicine in oncology, rheumatology, diabetes and many other disease categories.
For healthcare providers, the availability of biosimilars not only provides a broader array of therapeutic options, it also offers an alternative way to manage the cost of care. However, biosimilars also create new questions for providers, and many seek to better understand the clinical profile and economics of the therapies before prescribing them.
Interested in exploring biosimilars further? Cardinal Health has proven expertise and services to help.